Navigation Links
Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
Date:11/27/2011

pleased to have enrolled the first patient in this pivotal clinical study."

Inspiration in-licensed OBI-1 from Ipsen as part of their January 2010 partnership agreement, whereby Inspiration is responsible for the clinical development, regulatory approval and commercialization of the product.  Previously, in November 2010, Inspiration initiated the first pivotal study of OBI-1 for the treatment of individuals with acquired hemophilia A, a rare, potentially life-threatening autoimmune bleeding disorder caused by the development of inhibitors against endogenous FVIII.  Results from the first patients in this clinical study were presented in a Scientific Session held in conjunction with the 23rd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in July 2011.  Enrollment in the OBI-1 acquired hemophilia clinical trial is ongoing.

John P. Butler, Chief Executive Officer of Inspiration, commented, "Inspiration is committed exclusively to driving innovation that can bring positive impact to the treatment of people with hemophilia.  We now have OBI-1 in pivotal development for multiple indications.  We also recently announced the filing of a Marketing Authorization Application (MAA) for our other lead program, IB1001, a recombinant factor IX product for the treatment of hemophilia B.  These two late stage products, along with our preclinical programs for factor VIIa and FVIII deficiency, gives Inspiration one of the broadest pipelines for hemophilia treatment in the industry.  As a company, we are committed to developing and commercializing an array of hemophilia products, which will provide value to physicians and to people living with the condition worldwide."

About HemophiliaHemophilia is a bleeding disorder caused by low levels or the absence of a protein called a coagulation factor, essential for blood clotting.  The two most common forms of hemophilia are types A and B.  Hemop
'/>"/>

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
2. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
3. Inspiration for My Sisters Keeper Speaks Out
4. National Expressions of Courage Art Contest Unveils Stories of Inspiration
5. Inspiration Biopharmaceuticals OBI-1 Receives Orphan Drug Designation in Europe
6. Inspiration Biopharmaceuticals Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
7. Siemens MAMMOMAT Inspiration Digital Mammography Commercially Available in U.S.
8. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
9. Inspiration Biopharmaceuticals Demonstrates Non-Inferiority of IB1001, Its Recombinant Factor IX for Hemophilia B
10. Inspiration Biopharmaceuticals Announces Data from OBI-1 Pivotal-Stage Program in Hemophilia at 23rd ISTH Congress
11. Heskas 2011 "Inspiration in Action" Contest Begins: Support the Veterinary Profession and Help Animals in Need
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Ala. , July 14, 2014  Patients and ... patients as Express Scripts and other major pharmacy benefit ... The cuts will directly impact millions of patients who ... medical conditions, including persistent pain from cancer, diabetes and ... begin notifying some patients on July 15. ...
(Date:7/14/2014)... , 14 de julio de 2014 /PRNewswire-HISPANIC PR WIRE/ ... que Barry Epling , presidente de la junta ... de la Compañía. El señor Epling es el dueño ... otorgó la licencia de su formulación, sus propiedades intelectuales ... de apoyo financiero. "El señor Gerald ...
(Date:7/14/2014)... CITY , July 14, 2014  Remedy ... software for healthcare delivery and life sciences research, ... National Pancreas Foundation (NPF) to build the first-ever ... including pancreatic cancer and pancreatitis. "The ... the evolutionary change that thoughtful and committed organizations ...
Breaking Medicine Technology:Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 2Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 4BioAdaptives se prepara para el próximo paso 2BioAdaptives se prepara para el próximo paso 3Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 2Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 3
(Date:7/14/2014)... brain injury specialists look back on 40 years of the ... scale in research and clinical practice, in a new Personal ... , The Personal View is published on the 40th ... Lancet article*. Since this seminal publication, the Glasgow Coma ... impairment of conscious level, the clinical hallmark of acute brain ...
(Date:7/14/2014)... 2014 A recent study published in the July ... Academy of Child and Adolescent Psychiatry confirms the ... onset criterion for diagnosis of attention-deficit/hyperactivity disorder (ADHD). , ... set at 7 in DSM-IV, has been raised to ... now set at 12, rather than an earlier age, ...
(Date:7/14/2014)... the company Tissuegnostics, the pathologist Lukas Kenner and his ... identify cancer cells in tissue sections and demonstrate the ... provides a precise picture of the disease and leads ... the results of the study, "Two independent pathologists concur ... diagnosis." , "The recently developed software offers, for the ...
(Date:7/14/2014)... and Hauppauge, NY (PRWEB) July 14, 2014 ... (RGONY), with offices in Hicksville and Hauppauge, NY, ... implant) as a long-lasting treatment for diabetic macular ... Allergan, recently obtained an additional FDA-approved indication for ... approved by the FDA in 2009 for treatment ...
(Date:7/14/2014)... There’s an old adage that says first ... Palette say the products offered in their preorder event ... can reserve The Lash Palette for $40,” said Jenelle Paris, ... , Paris explained that the first 1,000 have already been ... She went on to point out that her company is ...
Breaking Medicine News(10 mins):Health News:Scientists developed new technology for the diagnosis of cancer cells 2Health News:Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy 2Health News:Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy 3Health News:The Lash Palette Preorder Event Has Officially Begun 2
... , , Improvement ... ROSEMONT, Ill., Aug. 3 A new study published in ... Joint Surgery (JBJS) finds that two years after anterior cervical ... can be expected to have significant improvement in their headache symptoms. , ...
... LOUIS, Aug. 3 Not just for teens anymore--social networking and ... by adults to interact with their friends, families and to gain ... these tools to the list of ways to interact with their ... its members like never before, Anthem Blue Cross and Blue Shield ...
... Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com ... division have reported results on experiments in which ... after traumatic brain injury have been explored. These ... the Hyperbaric Medical Center, School of Medicine, University ...
... The ... Harper, Jason Mraz, G. Love & others , ... Los Angeles, CA (PRWEB) August 3, 2009 -- Domestix, a Beverly Hills based domestic sales ... Thursday, August 6th at the Malibu Cinemas. "Domestix is thrilled to be involved with Jesse,s Story. ...
... PLAINSBORO, N.J., Aug. 3 Pharmacy & Healthcare Communications, LLC ... Pharmacy Times , a monthly journal that reaches the ... as well as its website, www.PharmacyTimes.com , ... custom supplements, including Pharmacy Times Careers ...
... By injecting man-made, microscopic tubes into tumors and heating ... have discovered a way to effectively kill kidney tumors in ... suggests a potential future cancer treatment for humans. The ... of the National Academy of Sciences ). It is the ...
Cached Medicine News:Health News:Neck Surgery for Cervical Spine Disorders Found to Alleviate Associated Headaches 2Health News:Neck Surgery for Cervical Spine Disorders Found to Alleviate Associated Headaches 3Health News:Anthem Blue Cross and Blue Shield in Missouri Harnesses Social Media to Interact with Members 2Health News:Anthem Blue Cross and Blue Shield in Missouri Harnesses Social Media to Interact with Members 3Health News:Hard to Treat Diseases, Inc. (HTDS) Experiments with Hyperbaric Oxygenation (HBO) Traumatic Brain Injury 2Health News:Hard to Treat Diseases, Inc. (HTDS) Experiments with Hyperbaric Oxygenation (HBO) Traumatic Brain Injury 3Health News:Hard to Treat Diseases, Inc. (HTDS) Experiments with Hyperbaric Oxygenation (HBO) Traumatic Brain Injury 4Health News:"Jesse's Story" to Open The 10th Annual Malibu Film Festival 2Health News:"Jesse's Story" to Open The 10th Annual Malibu Film Festival 3Health News:Pharmacy Times Names New Editorial Director 2Health News:Researchers effectively treat tumors with use of nanotubes 2Health News:Researchers effectively treat tumors with use of nanotubes 3
This double-up gel dryer system, 100-120 V, includes 2 Model 583 gel dryers, HydroTech™ vacuum pump, and double-up rack....
... GelAir™ drying system utilizes a hot air drying ... dried on a clear cellophane support for easy ... a smooth, flat assembly surface for the drying ... frames at once. This 115 V, 60 Hz ...
... is an electrophoresis gel vacuum dryer that removes ... these gels onto cellophane or filter paper for ... which heat gels from above. The drying surface ... unit includes power cord, porous gel support, transparent ...
... The PRO6000 power supply is ... power supply product offering. It ... and genomic electrophoresis. This product ... proteomic applications such as microAmp ...
Medicine Products: